Abstract
Translational research and translational medicine (referred to hereafter as translational research) are interchangeable terms that underline the pressing need to translate into practical benefits for those affected by disease the extensive investments divested by the private and public sectors in biomedical research. For people more directly involved in clinical practice (physicians, clinical laboratory professionals and patients), translational research responds to the need to accelerate the capture of benefits of research, closing the gap between what we know and what we practice. This basically means the transfer of diagnostic and therapeutic advances proven effective in large, well-conducted trials (and, therefore, evidence-based) to daily medical practice. Translational research should be regarded as a two-way road: bench to bedside, and bedside to bench. In particular, to make possible a more effective translation process, a new road map should be implemented through interaction and cooperation between basic researchers, clinicians, laboratory professionals and manufacturers. Some examples of recent developments in clinical laboratory testing, including markers of cardiovascular diseases, clinical proteomics and recombinant allergens, may explain the importance of careful evaluation of all variables that allow the introduction of such new insights into clinical practice to assure better clinical outcomes. The vital role of laboratory medicine in the delivery of safer and more effective healthcare requires more careful evaluation not only of the analytical characteristics, but also of any other variable that may affect the clinical usefulness and diagnostic performances of laboratory tests, thus allowing more accurate interpretation and utilization of laboratory information.
Clin Chem Lab Med 2006;44:1303–12.
References
1. Pober JS, Neuhauser CS, Pober JM. Obstacles facing translational research in academic medical centers. FASEB J 2001; 15:2303–13.10.1096/fj.01-0540lsfSearch in Google Scholar
2. Institute of Medicine. Academic Health Centers. Leading change in the 21st century. Washington, DC: The National Academies Press, 2004.Search in Google Scholar
3. Davis D, Evans M, Jadad A, Perrier L, Rath D, Ryan D, et al. The case for knowledge translation: shortening the journey from evidence to effect. Br Med J 2003; 327:33–5.10.1136/bmj.327.7405.33Search in Google Scholar
4. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. J Am Med Assoc 1999; 281:627–33.10.1001/jama.281.7.627Search in Google Scholar
5. Konh LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: Academic Press, 2000.Search in Google Scholar
6. Bion JF, Heffner JE. Challenges in the care of the acutely ill. Lancet 2004; 363:970–7.10.1016/S0140-6736(04)15793-0Search in Google Scholar
7. Leape LL, Berwick DM. Five years after To Err Is Human. J Am Med Assoc 2005; 293:2384–90.10.1001/jama.293.19.2384Search in Google Scholar PubMed
8. Chassin MR, Galvin RW. The urgent need to improve health care quality. J Am Med Assoc 1998; 280:1000–5.10.1001/jama.280.11.1000Search in Google Scholar PubMed
9. Ross JS, Ginsburg GS. The integration of molecular diagnostics with therapeutics. Am J Clin Pathol 2003; 119:26–36.10.1309/VMLL66Y5KHQ35KUESearch in Google Scholar
10. Canadian Institutes of Health Research. Knowledge translation framework. www.cihr-ircs.gc.ca/cgi-bin/print-imprimer.pl. Accessed September 7, 2005.Search in Google Scholar
11. Crowley WF, Sherwood L, Salberg P, Scheinberg D, Slavkin H, Tilson H, et al. Clinical research in the United States at a crossroads. J Am Med Assoc 2004; 291:1120–6.10.1001/jama.291.9.1120Search in Google Scholar PubMed
12. Price CP. Evidence-based laboratory medicine: supporting decision-making. Clin Chem 2000; 46:1041–50.10.1093/clinchem/46.8.1041Search in Google Scholar
13. Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in translation: obstacles to translational medicine. J Transl Med 2004; 2:14–8.10.1186/1479-5876-2-14Search in Google Scholar PubMed PubMed Central
14. Peters K. Exceptional matters. Lancet 2004; 364:2142–51.10.1016/S0140-6736(04)17556-9Search in Google Scholar
15. Pickles H. Using lessons from the past to plan for pandemic flu. Br Med J 2006; 332:783–6.10.1136/bmj.332.7544.783Search in Google Scholar
16. Andrei A, Zervos MJ. The application of molecular techniques to the study of hospital infection. Arch Pathol Lab Med 2006; 130:662–8.10.5858/2006-130-662-TAOMTTSearch in Google Scholar
17. Muller MP, Richardson SE, McGeer A, Dresser L, Raboud J, Mazzulli T, et al. Early diagnosis of SARS: lessons from the Toronto SARS outbreak. Eur J Clin Microbiol Infect Dis 2006; 25:230–7.10.1007/s10096-006-0127-xSearch in Google Scholar
18. Partridge WM. Translational science: what is it and why is it so important? Drug Discovery Today 2003; 8:813–5.10.1016/S1359-6446(03)02823-XSearch in Google Scholar
19. Marincola FM. Translational medicine: a two-way road. J Transl Med 2003; 1:1–2.10.1186/1479-5876-1-1Search in Google Scholar PubMed PubMed Central
20. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 2005; 357:113–22.10.1016/j.cccn.2005.03.017Search in Google Scholar PubMed
21. Lenfant C. Clinical research to clinical practice – lost in translation? N Engl J Med 2003; 349:868–74.10.1056/NEJMsa035507Search in Google Scholar PubMed
22. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352:1685–95.10.1056/NEJMra043430Search in Google Scholar PubMed
23. Rosalki SB, Roberts R, Katus HA, Giannitis E, Ladenson JH, Apple FS. Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem 2004; 50:2205–13.10.1373/clinchem.2004.041749Search in Google Scholar PubMed
24. Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin Chem Lab Med 2003; 41:871–83.10.1515/CCLM.2003.132Search in Google Scholar
25. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959–69.10.1016/S0735-1097(00)00804-4Search in Google Scholar
26. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for the detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810–24.10.1373/clinchem.2004.046292Search in Google Scholar PubMed
27. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003; 349:1587–9.10.1056/NEJMp038136Search in Google Scholar PubMed
28. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwing LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49:7–18.10.1373/49.1.7Search in Google Scholar PubMed
29. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, et al. N-Terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110:128–34.10.1161/01.CIR.0000134480.06723.D8Search in Google Scholar PubMed
30. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363–9.10.1161/01.CIR.0000053730.47739.3CSearch in Google Scholar PubMed
31. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003; 108:250–2.10.1161/01.CIR.0000078080.37974.D2Search in Google Scholar PubMed
32. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. J Am Coll Cardiol 2006; 48:1–11.10.1016/j.jacc.2006.02.056Search in Google Scholar PubMed
33. Moons KG, Biesheuvel CJ, Grobbee DE. Test research versus diagnostic research. Clin Chem 2004; 50:473–4.10.1373/clinchem.2003.024752Search in Google Scholar PubMed
34. Heim SW, Schectman JM, Siadaty MS, Philbrick JT. D-Dimer testing for deep venous thrombosis: a meta-analysis. Clin Chem 2004; 50:1136–47.10.1373/clinchem.2004.031765Search in Google Scholar
35. Stein PD, Hull RD, Patel KC, Olson RE, Ghall WA, Brant R, et al. D-Dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Int Med 2004; 140:589–602.10.7326/0003-4819-140-8-200404200-00005Search in Google Scholar
36. McDermott MM, Ferrucci L, Liu K, Criqui MH, Greenland P, Green D, et al. D-Dimer and inflammatory markers as predictors of functional decline in men and women with and without peripheral arterial disease. J Am Geriatr Soc 2005; 53:1688–96.10.1111/j.1532-5415.2005.53510.xSearch in Google Scholar
37. Plebani M, Zaninotto M. Diagnostic strategies using myoglobin measurement in myocardial infarction. Clin Chim Acta 1998; 272:69–77.10.1016/S0009-8981(97)00253-2Search in Google Scholar
38. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, et al. The diagnostic approach to acute venous thromboembolism: clinical practice guideline: American Thoracic Society. Am J Respir Crit Care Med 1999; 160:1043–66.10.1164/ajrccm.160.3.16030Search in Google Scholar
39. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365:1163–74.10.1016/S0140-6736(05)71880-8Search in Google Scholar
40. Plebani M. The future of clinical laboratories: more testing or knowledge services? Clin Chem Lab Med 2005; 43:893–6.10.1515/CCLM.2005.152Search in Google Scholar PubMed
41. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2003;26(Suppl 1):S94–8.10.2337/diacare.26.2007.S94Search in Google Scholar PubMed
42. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254:45–66.10.1046/j.1365-2796.2003.01157.xSearch in Google Scholar PubMed
43. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens 2004; 6(Suppl 3):2–7.10.1111/j.1524-6175.2004.4064.xSearch in Google Scholar PubMed PubMed Central
44. Viberti GC, Keen H. Microalbuminuria and diabetes. Lancet 1983; 12:352–3.Search in Google Scholar
45. Busby DE, Bakris GL. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens 2004; 6(Suppl 3):8–12.10.1111/j.1524-6175.2004.04237.xSearch in Google Scholar
46. Osicka TM, Houlihan CA, Chan JC, Jerums G, Comper WD. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000; 49:1579–84.10.2337/diabetes.49.9.1579Search in Google Scholar
47. Greive KA, Balazs ND, Comper WD. Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 2001; 47:1717–9.10.1093/clinchem/47.9.1717Search in Google Scholar
48. Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis 2003; 41:336–42.10.1053/ajkd.2003.50041Search in Google Scholar
49. Peters T. New forms of urinary albumin in early diabetes. Clin Chem 2004; 50:2238–9.10.1373/clinchem.2004.040998Search in Google Scholar
50. Wilkins MR, Williams KL, Appel RD, Hochstrasser DF, editors. Proteome research: new frontiers in functional genomics. Berlin: Springer, 1997:243 pp.Search in Google Scholar
51. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996; 13:19–50.10.1080/02648725.1996.10647923Search in Google Scholar
52. Petricoin EF III, Ardekani AM, Hitt BA, Levine P, Fusaro VA, Steinberg S, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572–7.10.1016/S0140-6736(02)07746-2Search in Google Scholar
53. Petricoin EF III, Omstein DK, Paweletz CP, Ardekani AM, Hackett PS, Hitt BA. Serum proteomic patterns for detection of prostatic cancer. J Natl Cancer Inst 2002; 94:1576–8.10.1093/jnci/94.20.1576Search in Google Scholar PubMed
54. Adam BL, Qu Y, Davies JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609–14.Search in Google Scholar
55. Diamandis EP. Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49:1272–8.10.1373/49.8.1272Search in Google Scholar PubMed
56. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005; 51:3–5.10.1373/clinchem.2004.043281Search in Google Scholar PubMed
57. White CN, Chan DW, Zhang Z. Bioinformatics strategies for cancer biomarker discovery. Clin Biochem 2004; 37:636–41.10.1016/j.clinbiochem.2004.05.004Search in Google Scholar
58. Petricoin EF III, Liotta LA. The vision for a new diagnostic paradigm. Clin Chem 2003; 49:1276–8.10.1373/49.8.1276Search in Google Scholar
59. Hortin GL. The MALDI TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006; 52:1223–37.10.1373/clinchem.2006.069252Search in Google Scholar
60. Hortin GL, Jortani SA, Ritchie JC, Valdes R, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006; 52:1218–22.10.1373/clinchem.2006.067280Search in Google Scholar
61. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82:233–48.10.1016/S1081-1206(10)62603-8Search in Google Scholar
62. Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13:381–94.Search in Google Scholar
63. Ishizaka K, Ishizaka T. Identification of γE-antibodies as a carrier of reaginic activity. J Immunol 1967; 99:1187–98.10.4049/jimmunol.99.6.1187Search in Google Scholar
64. Wide L, Bennich H, Johansson SG. Diagnosis of allergy by an in vitro test for allergen antibodies. Lancet 1967; 2:1105–7.10.1016/S0140-6736(67)90615-0Search in Google Scholar
65. Plebani M. Clinical value and measurement of specific IgE. Clin Biochem 2003; 36:453–69.10.1016/S0009-9120(03)00037-7Search in Google Scholar
66. Van der Veen MJ, Mulder M, Witteman AM, van Ree R, Aalberse RC, Janse HM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite allergens. J Allergy Clin Immunol 1996; 98:1028–32.10.1016/S0091-6749(96)80187-4Search in Google Scholar
67. Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995; 7:751–6.10.1016/0952-7915(95)80043-3Search in Google Scholar
68. Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R, et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991; 88:889–94.10.1016/0091-6749(91)90245-JSearch in Google Scholar
69. Mari A. Multiple pollen sensitization: a molecular approach to the diagnosis. Int Arch Allergy Immunol 2001; 125:57–65.10.1159/000053797Search in Google Scholar PubMed
70. Mothes N, Valenta R, Spitzauer S. Allergy testing: the role of recombinant allergens. Clin Chem Lab Med 2006; 44:125–32.10.1515/CCLM.2006.024Search in Google Scholar PubMed
71. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999; 29:896–904.10.1046/j.1365-2222.1999.00653.xSearch in Google Scholar PubMed
72. Deinhofer K, Sevcik H, Balic N, Harwanegg C, Hiller R, Rumpold H. Microarrayed allergens for IgE profiling. Methods 2004; 32:249–54.10.1016/j.ymeth.2003.08.018Search in Google Scholar PubMed
73. Harwanegg C, Hiller R. Protein microarray for the diagnosis of allergic diseases: state-of-the-art and future development. Clin Chem Lab Med 2005; 43:1321–6.10.1515/CCLM.2005.226Search in Google Scholar PubMed
74. Kattan MW. Judging new makers by their ability to improve predictive accuracy. J Natl Cancer Inst 1989; 81:1879–86.Search in Google Scholar
75. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2002; 2:4.10.1186/1471-2288-2-4Search in Google Scholar PubMed PubMed Central
76. Pepe MS, James H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159:882–90.10.1093/aje/kwh101Search in Google Scholar PubMed
77. Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology 2005; 16:598–603.10.1097/01.ede.0000173041.03470.8bSearch in Google Scholar PubMed
78. Pfeiffer RM, Castle PE. With or without a gold standard. Epidemiology 2005; 16:595–7.10.1097/01.ede.0000173328.31497.ecSearch in Google Scholar PubMed
79. Rosenberg RN. Translating biomedical research to the bedside: a national crisis and a call to action. J Am Med Assoc 2003;289:1305–6.10.1001/jama.289.10.1305Search in Google Scholar PubMed
80. Snyderman R. The clinical researcher – an “emerging” species. J Am Med Assoc 2004; 291:882–3.10.1001/jama.291.7.882Search in Google Scholar PubMed
81. Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med 2005; 11:705–8.10.1038/nm0705-705Search in Google Scholar PubMed
82. Zerhouni EA. Translational and clinical science – time for a new vision. N Engl J Med 2005; 353:1621–3.10.1056/NEJMsb053723Search in Google Scholar PubMed
83. Plebani M, Laposata M. Translational research involving new biomarkers of disease: a leading role for the pathologist. Am J Clin Pathol 2006; 126:169–71.10.1309/5GHY0VCWBUY58EFXSearch in Google Scholar
©2006 by Walter de Gruyter Berlin New York
